Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$56.22 USD

56.22
1,419,026

-1.62 (-2.80%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $56.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Globus Medical (GMED) Gains on Innovation, Strategic Deal

by Zacks Equity Research

Globus Medical's (GMED) Enabling technology sales improvement is driven by strong performance of its robotic and imaging system.

Zacks Equity Research

ITGR or GMED: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ITGR vs. GMED: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

New product developments and the pending NuVasive acquisition raise optimism about the Globus Medical (GMED) stock.

Zacks Equity Research

Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe

by Zacks Equity Research

Globus Medical (GMED) continues to make significant progress in launching its prone lateral patient positioning system.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.

Zacks Equity Research

Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod

by Zacks Equity Research

Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.

Zacks Equity Research

Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips

by Zacks Equity Research

The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.

Zacks Equity Research

Globus Medical (GMED) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of 3.92% and 8.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 3.28% and 10.38%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Globus' (GMED) NUVA Buyout Seems Strategic, Cost Woe Stays

by Zacks Equity Research

Globus Medical (GMED) and NuVasive (NUVA) are currently planning to combine in an all-stock transaction to create a global musculoskeletal company.

Zacks Equity Research

Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs

by Zacks Equity Research

The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.

Zacks Equity Research

NuVasive (NUVA), GMED Merger Aids, Macro Woes Mar Growth

by Zacks Equity Research

According to NuVasive (NUVA), the combined company is set to have an advanced commercial scale and portfolio of clinically proven solutions.

Zacks Equity Research

Globus Medical (GMED) Q4 Earnings Beat, Operating Margin Rises

by Zacks Equity Research

Globus Medical (GMED) reports strong fourth-quarter sales growth amid currency headwinds and lingering COVID-19 impacts.

Zacks Equity Research

Globus Medical (GMED) Tops Q4 Earnings Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of 7.27% and 0.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Shockwave Medical (SWAV) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 274.75% and 1.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Steris (STE) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of -9.01% and 4.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Nevro (NVRO): Can Its 5.1% Jump Turn into More Strength?

by Zacks Equity Research

Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Here's Why Investors Should Retain Globus Medical (GMED) Stock

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) robust performance across several international markets.

Zacks Equity Research

Globus Medical (GMED) Global Growth Strong Despite Margin Woe

by Zacks Equity Research

Despite continued margin declines in Japan, Globus Medical (GMED) remains positive on the progress and potential of its international business for long-term growth as it continues to reset the market in the country.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings Miss Estimates, EPS View Cut

by Zacks Equity Research

Internationally, Globus Medical (GMED) reports double-digit growth in most markets, with the U.K., Australia, Brazil, India and Poland registering more than 40% growth.

Zacks Equity Research

Company News for Nov 10, 2022

by Zacks Equity Research

Companies In The News Are: AKAM, AXON, GMED, SRC.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings Lag Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of -3.85% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

CVRx (CVRX) delivered earnings and revenue surprises of 14.29% and 5.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?